ArticleBMC oral health2026
Risk factors and clinical outcomes of oral mucositis in patients undergoing hematopoietic stem cell transplantation: a retrospective study of 551 cases.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOral mucositis (OM) is a common complication in hematopoietic stem cell transplantation (HSCT). This study aimed to analyze OM characteristics, risk factors, and preventive strategies.
methodsMedical records of 551 patients undergoing HSCT from June 2019 to June 2022 were retrospectively reviewed. OM incidence, clinical features, and associated risk factors were analyzed.
results128 patients (23.2%) developed OM, peaking 7 days after stem cell infusion. Autologous transplantation reduced OM risk by 84.5%, while periodontitis and prior oral symptoms during chemotherapy increased risk by 111.4% and 140.7%, respectively. OM was associated with longer hospitalization and more febrile days. Symptoms were managed effectively with mouthwash, antibiotics, and ultraviolet therapy.
conclusionsOM is common in HSCT patients and can be effectively controlled. Allogeneic transplantation, pre-existing oral conditions, and periodontitis increase OM risk, highlighting the importance of pre-transplant oral care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.